Gag-specific cytotoxic responses to HIV type 1 are associated with a decreased risk of progression to AIDS-related complex or AIDS.
Gag-specific cytotoxic responses to HIV type 1 are associated with a decreased risk of progression to AIDS-related complex or AIDS.
复制标题
DOI：
10.1089/aid.1995.11.903
复制
发表时间：
1995-08
影响因子：
1.5
通讯作者：
Y. Rivière;M. McChesney;F. Porrot;F. Tanneau-Salvadori;P. Sansonetti;O. Lopez;G. Pialoux;V. Feuillie;M. Mollereau;S. Chamaret;F. Tekaia;L. Montagnier
中科院分区：
文献类型：
--
作者：
Y. Rivière;M. McChesney;F. Porrot;F. Tanneau-Salvadori;P. Sansonetti;O. Lopez;G. Pialoux;V. Feuillie;M. Mollereau;S. Chamaret;F. Tekaia;L. Montagnier
人类免疫缺陷病毒(HIV-1)感染艾滋病之前的持续时间是可变的，对大多数患者来说，感染的确切时间是未知的。一组38名HIV-1感染者在无症状的情况下对HIV-1的Gag和包膜抗原的比较细胞毒性淋巴细胞反应进行了测试。在38名患者中，有20名患者对GAG没有检测到初级细胞毒性T淋巴细胞(CTL)反应，与观察期开始时有GAG特异性CTL活性的患者相比，在随后的3至40个月的观察中，进展为ARC或艾滋病的相对风险为1.89。相反，没有观察到包膜特异性细胞毒活性与疾病进展之间的显著关联。其他患者特征，包括CD4+T淋巴细胞计数和p24gag蛋白抗体水平，在观察开始时测量，与观察期内的疾病进展无关。这表明抗Gag CTL反应在HIV-1感染过程中可能具有保护性作用。
The duration of human immunodeficiency virus (HIV-1) infection prior to the development of AIDS is variable, and for most patients the exact time of infection is not known. A group of 38 HIV-1-infected subjects was tested while asymptomatic for comparative cytotoxic lymphocyte responses to the Gag and envelope antigens of HIV-1. Twenty of the 38 patients had no detectable primary cytotoxic T lymphocyte (CTL) response to Gag, and this was associated with a relative risk of 1.89 for progression to ARC or AIDS during the subsequent 3 to 40 months of observation when compared with patients who had Gag-specific CTL activity at the beginning of the observation period. In contrast, no significant association was observed between envelope-specific cytotoxic activity and disease progression. Other patient characteristics, including CD4+ T lymphocyte counts and antibody levels to the p24gag protein, measured at the start of observation, did not correlate with disease progression during the observation period. This suggests that the anti-Gag CTL response may be protective during HIV-1 infection.